Methods to enable cholesterol catabolism in human monocyte derived macrophages

在人单核细胞衍生的巨噬细胞中实现胆固醇分解代谢的方法

• 批准号: 8668135
• 负责人: RICHARD E HONKANEN
• 金额: $ 33.41万
• 依托单位: UNIVERSITY OF SOUTH ALABAMA
• 依托单位国家: 美国
• 财政年份: 2011
• 资助国家: 美国
• 起止时间: 2011-09-23 至 2016-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8668135
• 关键词: Address; Animal Model; Arterial Fatty Streak; Atherosclerosis; Bacteria; Bacterial Genes; Biochemical; Carbon Dioxide; Cardiovascular Diseases; Catabolism; Cause of Death; Cell Therapy; Cholestanes; Cholesterol; Cholesterol Esters; Clinical Trials; Complex; Coronary; Development; Disease; Enzymes; Event; Gene Expression; Genes; Genetic; Genus Mycobacterium; Goals; High Density Lipoproteins; Human; Immune response; Individual; Lead; Life Style; Lipoproteins; Medical; Methods; Myocardial Infarction; Pathway interactions; Phagosomes; Plasma; Production; Progressive Disease; Staging; Stroke; System; Testing; Transfection; United States; Vascular Diseases; age related; design; expression vector; feeding; high risk; innovation; lipid metabolism; macrophage; monocyte; novel strategies; prevent; promoter; response

DESCRIPTION (provided by applicant): Atherosclerotic cardiovascular disease (CVD) is the leading cause of death in the United States. CVD originates from aberrations in normal lipid metabolism (some genetic, some lifestyle choices) that result in elevated plasma lipoproteins (principally LDLs) and/or low levels of high-density lipoproteins (HDLs). For many people, CVD is an age dependent, progressive disease that is largely undetected or ignored until an event (i.e. myocardial infarction or stroke) occurs in the later stages of disease. Therefore, current therapies focus on preventing a second event (or a primary event in high risk individuals) by reducing the circulating levels of LDLs and/or increasing HDLs. However, at a biochemical level the inability of macrophages to degrade the cholestane ring of cholesterol is a fundamental component of CVD. If macrophages had the ability to degrade cholesterol, they would not become engorged with cholesterol/cholesterol esters and elicit the maladaptive immune response that leads to the onset and progression of atherosclerosis. Recently, studies of Mycobacteria survival in human macrophages revealed a surprising observation. Mycobacteria feed on cholesterol while contained in the phagosomes of macrophages. Importantly, two enzymes that catalyze cholestane ring opening have been identified. We plan to test the hypothesis that genes encoding enzymes identified in bacteria can be humanized and used to transformation human monocyte derived macrophages, enabling the degradation of phagosome-cholesterol. The main objectives are to: 1) humanize bacterial genes encoding key ring opening enzymes, 2) develop an innovative expressions systems to regulate the expression of these genes in response to changes in cellular levels of cholesterol, and 3) characterize the production and fate of compounds generated following B-ring opening. If this paradigm-challenging hypothesis is true, the proposed studies should lead to the development of an entirely new approach for the medical management of CVD.

描述（由申请人提供）：动脉粥样硬化性心血管疾病（CVD）是美国的主要死亡原因。心血管疾病起源于正常脂质代谢的异常（一些是遗传的，一些是生活方式的选择），导致血浆脂蛋白（主要是ldl）升高和/或高密度脂蛋白（hdl）水平降低。对许多人来说，心血管疾病是一种年龄依赖性的进行性疾病，在疾病晚期发生事件（如心肌梗死或中风）之前，在很大程度上未被发现或忽视。因此，目前的治疗重点是通过降低ldl循环水平和/或增加hdl来预防第二次事件（或高危人群的主要事件）。然而，在生化水平上，巨噬细胞无法降解胆固醇的胆甾烷环是心血管疾病的基本组成部分。如果巨噬细胞具有降解胆固醇的能力，它们就不会充满胆固醇/胆固醇酯，从而引发导致动脉粥样硬化发生和发展的不适应免疫反应。最近，对分枝杆菌在人巨噬细胞中存活的研究揭示了一个令人惊讶的观察结果。分枝杆菌以含有在巨噬细胞吞噬体中的胆固醇为食。重要的是，已经确定了两种催化胆甾烷环打开的酶。我们计划验证在细菌中发现的编码酶的基因可以人源化并用于转化人类单核细胞来源的巨噬细胞，从而使吞噬体胆固醇降解的假设。主要目标是：1)使编码关键环打开酶的细菌基因人性化；2)开发一种创新的表达系统来调节这些基因的表达，以响应细胞胆固醇水平的变化；3)表征b环打开后产生的化合物的产生和命运。如果这种挑战范式的假设是正确的，那么提出的研究应该会导致CVD医学管理的全新方法的发展。